MEDFORD, NY and SEATTLE, WA -- (MARKET WIRE) -- May 23, 2007 -- Chembio Diagnostics, Inc. (OTCBB: CEMI) and the Infectious Disease Research Institute (IDRI) have entered into two research and development agreements for the development of rapid diagnostic tests for Leishmaniasis and Leprosy, two “neglected diseases” targeted by IDRI. The tests will be developed by Chembio using Chembio’s patented Dual Path immunoassay test platform (DPP™) and will incorporate IDRI proprietary antigens.
